Urinary miRNAs Research Articles

Investigation of Urinary Exosomal miRNA and lncRNA Expression Profiles and ceRNA Network in Diabetic Kidney Disease

Investigation of Urinary Exosomal miRNA and lncRNA Expression Profiles and ceRNA Network in Diabetic Kidney Disease

Biomarkers for Prostate Cancer: From Diagnosis to Treatment.

Prostate cancer (PCa) is a widespread malignancy with global significance, which substantially affects cancer-related mortality. Its spectrum varies widely, from slow-progressing cases to aggressive or even lethal forms. Effective patient stratification into risk groups is crucial to therapeutic decisions and clinical trials. This review examines a wide range of diagnostic and prognostic biomarkers, several of which are integrated into clinical guidelines, such as the PHI, the 4K score, PCA3, Decipher, and Prolaris. It also explores the emergence of novel biomarkers supported by robust preclinical evidence, including urinary miRNAs and isoprostanes. Genetic alterations frequently identified in PCa, including BRCA1/BRCA2, ETS gene fusions, and AR changes, are also discussed, offering insights into risk assessment and precision treatment strategies. By evaluating the latest developments and applications of PCa biomarkers, this review contributes to an enhanced understanding of their role in disease management.

Clinical significance of urinary exosomal microRNAs in patients with IgA nephropathy

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. The clinical relevance of 11 urinary exosomal microRNAs (miRNAs) was evaluated in patients with IgAN. From January 2009 to November 2018, IgAN (n = 93), disease control (n = 11), and normal control (n = 19) groups were enrolled. We evaluated the expression levels of urinary exosomal miRNAs at the baseline and their relationship with clinical and pathologic features. This study aimed to discriminate statistically powerful urinary exosomal miRNAs for the prognosis of IgAN. Urinary miRNA levels of miR-16-5p, miR-29a-3p, miR-124-3p, miR-126-3p, miR-199a-3p, miR-199b-5p, and miR-335-3p showed significant correlation with both estimated glomerular filtration rate (eGFR) and urine protein-to-creatinine ratio (uPCR). In univariate regression analysis, age, body mass index, hypertension, eGFR, uPCR, Oxford classification E, and three miRNAs (miR-16-5p, miR-199a-3p, and miR-335-3p) were associated with disease progression in patients with IgAN. The area under the curve (AUC) of miR-199a-3p was high enough (0.749) without any other clinical or pathologic factors, considering that the AUC of the International IgAN Risk Prediction Tool was 0.853. Urinary exosomal miRNAs may serve as alternative prognostic biomarkers of IgAN with further research.

Urinary miRNAs Predict Metastasis in Patients With Clinically Localized Clear Cell Renal Cell Carcinoma Treated With Nephrectomy

PurposePatients with clear cell renal cell carcinoma (ccRCC) might develop metastasis after surgery with curative intent. We aimed to characterize the expression levels of microRNAs in the urine (UmiRNAs) of patients before and after nephrectomy to determine the impact of UmiRNAs expression in the emergence of metastases. MethodsWe prospectively collected pre- and post-nephrectomy urine samples from 117 patients with clinically localized and locally advanced ccRCC. UmiRNAs were extracted, purified, and measured using RT-PCR. Relative quantifications (RQ) of 137 UmiRNAs were calculated through 2−∆∆ method. The post-surgery/pre-surgery RQs ratio represented the magnitude of the expression levels of the UmiRNAs. The association of UmiRNA expression and the development of distant metastases was tested with Cox regression model. ResultsFive UmiRNAs (miR-191-5p, miR-324-3p, miR-186-5p, miR-93-5p, miR-30b-5p) levels were upregulated before nephrectomy (p < .05). This conferred a 2- to 4-fold increased risk of metastasis, with miR-191-5p showing the most significant association with this endpoint (HR = 4.16, 95% CI = 1.38-12.58, p = .011). In a multivariate model stratified with stage and Fuhrman grade, we found that miR-191-5p, miR-324-3p, and miR-186-5p exhibited a strong association with metastasis development in patients with pathological T3 (pT3) tumors. Enrichment analysis with the most differentially expressed UmiRNAs showed that these UmiRNAs targeted genes that regulate cell survival and proliferation. ConclusionOur study indicated UmiR-191-5p, UmiR-324-3p, and UmiR-186-5p are potential markers to predict the development of metastasis, particularly in pT3 patients. Patient summaryWe compared changes of UmiRNAs expression detected pre- and postnephrectomy of patients with ccRCC. Our findings suggest that UmiRNA expression likely reflects tumor-specific changes that can be promising to predict the metastasis development, particularly in patients with non-metastatic locally advanced ccRCC. If confirmed, these findings may be useful for surveillance protocols for adjuvant therapy protocols.

Enzyme-free nucleic acid and luminescent material cascade amplifications enable urinary dual miRNAs assay for non-invasive bladder cancer diagnosis

We presented a facile biosensing strategy for the detection of dual microRNAs (miRNA-21 and miRNA-126) in urine samples from bladder cancer (BC) patients. The fluorescent homogeneous detection of miRNAs was achieved by elaborate parallel catalytic hairpin assembly (CHA) integrated with material cascade amplifications. The continuous release of G-quadruplex (G4) sequences and Hg2+ was attributed to the specific recognition between the miRNAs and the corresponding hairpin oligonucleotides. Assisted by the streptavidin-(T-Hg2+-T-biotin)4 structures, more Hg2+ emission was obtained, and the spatial site block effect was used to order its distribution, significantly improving the selective recognition performance of cadmium telluride quantum dots (CdTe QDs) (1.4–2.9 times). Furthermore, the peroxidase-like activity of G4-hemin was used to catalyze the oxidation of dopamine (DA) to fluorescence-enhanced polydopamine (PDA). The generated PDA signal and the Hg2+-quenched CdTe QDs signal completed the synchronous detection to achieve a high-sensitivity analysis of the dual miRNAs. The limit of detection (LOD) of both miRNAs was as low as the fM level. Eventually, 56 clinical urine samples were quantified. The results showed satisfying specificity (100%) and sensitivity (92%) with a strong clinical agreement, including computed tomography (CT) and pathology findings, indicating a rapid non-invasive solution for early diagnosis of BC.

Comparison of Serum and Urine as Sources of miRNA Markers for the Detection of Ovarian Cancer.

Ovarian cancer is the second most fatal gynecological cancer. Early detection, which could be achieved through widespread screening, has not yet had an impact on mortality. The aim of our pilot study was to investigate the expression of miRNAs analyzed by a human miRNA microarray chip in urine and serum of patients with ovarian cancer. We analyzed three serum and three urine samples from healthy donors and five serum and five urine samples from patients with ovarian cancer taken at first diagnosis, before any treatment. We selected the seven miRNAs with the highest expression fold change in the microarray chip (cancer vs. control) in urine and serum, for validation by qPCR. We were able to validate two of the seven miRNAs in serum. In contrast to these findings, we were able to validate all of the top seven miRNAs identified in urine using qPCR. The top seven miRNAs in urine identified by microarray chip showed significantly greater differences in expression between patients with ovarian cancer and healthy donors compared to serum. Based on our finding, we can suggest that urine as a biomaterial is more suitable than serum for miRNA profiling by microarray chip in the search for new biomarkers in ovarian cancer.

Transcriptomic profiling of urinary extracellular miRNAs in preeclampsia

Transcriptomic profiling of urinary extracellular miRNAs in preeclampsia

Visualization test strip reading of urine miRNA via cascade selective recognition reactions for non-invasive diagnosis of bladder cancer

This study proposed a homogeneous enzyme-free and nucleic acid-based catalytic hairpin assembly and cascade recognition reactions strategy that used calcein as the signal reporter for dual visualization (color and length) and fluorescence signal detection of bladder cancer marker miRNA-126 in clinical urine. This strategy was based on the ability of calcein and CuS nanoparticles (NPs) to recognize C-Ag+-C structure/Ag+/Cu2+/CuS NPs and C-Ag+-C structure/Ag+, respectively. Due to the integration of cascade amplification and material cation exchange reaction (CER), the sensitivity of homogeneous enzyme-free miRNA analysis at room temperature was significantly improved. This study achieved the limits of detections (LODs) as low as 0.25 aM of miRNA-126 and single-cell level of T24 cells with fluorescence mode. And the reading mode of color and length changes could detect miRNA and cells with concentrations as low as 5 aM and 1 cell/mL without instruments, respectively. And less reduction of fluorescence signal was observed when target miRNA was replaced with these base-mismatched RNAs. Then miRNA-126 in 66 clinical urine samples was quantified. The experimental results were consistent with the polymerase chain reaction (PCR) kit, computed tomography (CT), and pathological findings. The receiver operating characteristic (ROC) curve exhibited an area under the curve (AUC) value of 0.954, and the assay showed 100% specificity and 90% sensitivity.

Urinary MicroRNA Analysis Indicates an Epigenetic Regulation of Chronic Kidney Disease of Unknown Etiology in Sri Lanka.

Chronic kidney disease of unknown etiology (CKDu) is reported among male paddy farmers in the dry zone of Sri Lanka. The exact cause of this disease remains undetermined. Genetic susceptibility is identified as a major risk factor for CKDu Objectives: In this study, small urinary RNAs were characterized in CKDu patients, healthy endemic and non-endemic controls. Differently expressed urinary miRNAs and their associated pathways were identified in the study population. Healthy and diseased male volunteers (n = 9) were recruited from Girandurukotte (endemic) and Mawanella (non-endemic) districts. Urinary small RNAs were purified and sequenced using Illumina MiSeqTM. The sequence trace files were assembled and analyzed. Differentially ex-pressed miRNAs among these three groups were identified and pathway analysis was conducted. The urine samples contained 130,623 sequence reads identified as non-coding RNAs, PIWI-interacting RNAs (piRNA), and miRNAs. Approximately four percent of the total small RNA reads represented miRNA, and 29% represented piRNA. A total of 409 miRNA species were ex-pressed in urine. Interestingly, both diseased and endemic controls population showed significantly low expression of miRNA and piRNA. Regardless of the health status, the endemic population ex-pressed significantly low levels of miR-10a, miR-21, miR-148a, and miR-30a which have been linked with several environmental toxins Conclusion: Significant downregulation of miRNA and piRNA expression in both diseased and healthy endemic samples indicates an epigenetic regulation of CKDu involving genetic and environmental interaction. Further studies of specific miRNA species are required to develop a miRNA panel to identify individuals susceptible to CKDu.

Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.

MicroRNAs (miRNAs) are emerging as biomarkers for the detection and prognosis of cancers due to their inherent stability and resilience. To summarize the evidence regarding the role of urinary miRNAs (umiRNAs) in the detection, prognosis, and therapy of genitourinary cancers, we performed a systematic review of the most important scientific databases using the following keywords: (urinary miRNA) AND (prostate cancer); (urinary miRNA) AND (bladder cancer); (urinary miRNA) AND (renal cancer); (urinary miRNA) AND (testicular cancer); (urinary miRNA) AND (urothelial cancer). Of all, 1364 articles were screened. Only original studies in the English language on human specimens were considered for inclusion in our systematic review. Thus, a convenient sample of 60 original articles was identified. UmiRNAs are up- or downregulated in prostate cancer and may serve as potential non-invasive molecular biomarkers. Several umiRNAs have been identified as diagnostic biomarkers of urothelial carcinoma and bladder cancer (BC), allowing us to discriminate malignant from nonmalignant forms of hematuria. UmiRNAs could serve as therapeutic targets or recurrence markers of non-muscle-invasive BC and could predict the aggressivity and prognosis of muscle-invasive BC. In renal cell carcinoma, miRNAs have been identified as predictors of tumor detection, aggressiveness, and progression to metastasis. UmiRNAs could play an important role in the diagnosis, prognosis, and therapy of urological cancers.

Data Normalization of Urine miRNA Profiling from Head and Neck Cancer Patients Treated with Cisplatin.

The microRNA (miRNA) expression profile by qRT-PCR depends directly on the most appropriate normalization strategy adopted; however, currently there is no universally adequate reference gene. Therefore, this study aimed to determine, considering RNA-Seq results, the most adequate endogenous normalizer for use in the relative quantification of urine miRNAs from head and neck cancer patients, treated with cisplatin chemoradiotherapy. The massive sequencing was performed to identify the miRNAs differentially expressed between the group with cisplatin nephrotoxicity (n = 6) and the one without (n = 6). The candidate endogen normalizer was chosen according to four criteria: (1) the miRNA must be expressed in most samples; (2) the miRNA must have a fold change value between 0.99 and 1.01; (3) the miRNA must have a p-value ≥ 0.98; and (4) the miRNA must not be commented on by the final GeneGlobe (Qiagen, Hilden, Germany) analysis. Four miRNAs met all the criteria (hsa-miR-363-5p, hsa-miR-875-5p, hsa-miR-4302, and hsa-miR-6749-5p) and were selected for validation by qRT-PCR in a cohort of 49 patients (including the 12 sequencing participants). Only hsa-miR-875-5p was shown to be an adequate normalizer for the experimental condition under investigation, as it exhibited invariant expression between the two groups.

The Detection of Urinary Exosomal miRNAs for Cancer Diagnostics and Prognostics

The Detection of Urinary Exosomal miRNAs for Cancer Diagnostics and Prognostics

31 - Urinary exosomal miRNA profiles and target genes in bladder cancer: Pilot study

31 - Urinary exosomal miRNA profiles and target genes in bladder cancer: Pilot study

Urinary microRNAs in sepsis function as a novel prognostic marker.

Renal dysfunction is a common complication of sepsis. Early diagnosis and prompt treatment of sepsis with renal insufficiency are crucial for improving patient outcomes. Diagnostic markers can help identify patients at risk for sepsis and AKI, allowing for early intervention and potentially preventing the development of severe complications. The aim of the present study was to investigate the expression difference of urinary microRNAs (miRNAs/miRs) in elderly patients with sepsis and secondary renal insufficiency, and to evaluate their diagnostic value in these patients. In the present study, RNA was extracted from urine samples of elderly sepsis-related acute renal damage patients and the expression profiles of several miRNAs were analyzed. In order to evaluate the expression profile of several miRNAs, urine samples from elderly patients with acute renal damage brought on by sepsis were obtained. RNA extraction and sequencing were then performed on the samples. Furthermore, multiple bioinformatics methods were used to analyze miRNA profiles, including differential expression analysis, and Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis of different miRNA target genes, to further explore miRNAs that are suitable for utilization as biomarkers. A total of four miRNAs, including hsa-miR-31-5p, hsa-miR-151a-3p, hsa-miR-142-5p and hsa-miR-16-5p, were identified as potential biological markers and were further confirmed in sepsis using reverse transcription-quantitative PCR. The results of the present study demonstrated that the four urinary miRNAs were differentially expressed and may serve as specific markers for prediction of secondary acute kidney injury in elderly patients with sepsis.

Recent Progress on Urinary Exosomal miRNAs in Bladder Cancer

Bladder cancer (Bca) is one of the most common tumors in the urinary system. Cystoscopy biopsy is a gold standard for diagnosis of Bca in the clinic. However, cystoscopy biopsy is invasive, costly and invasive process causing pain in the patients. Because the Bca cells are closely in contact with urine, and the exosomes of the Bca can pass through the base membrane and transport the microRNA (miRNAs) to the urine, so the detection of the exosome-derived miRNAs in the urine is expected to be a new non-invasive method for diagnostics of Bca. Recently, liquid biopsy for miRNAs in urine is the recent research hotspot. In this review, we mainly introduce the feasibility of the application of the miRNAs from exosome to Bca, and its feasibility to detect Bca.

Nanoarchitectonics-Assisted Simultaneous Fluorescence Detection of Urinary Dual miRNAs for Noninvasive Diagnosis of Prostate Cancer.

Herein, we report a fluorescence strategy for the homogeneous and simultaneous analysis of urine miRNA-375 and miRNA-148a. The target miRNAs in urine bonded the devised dumbbell-shaped "C-Ag+-C" and "T-Hg2+-T" hairpin structures that could trigger cascade enzyme-free amplification. Then, the fluorescent CdTe quantum dots (QDs) and carbon dots (CDs) could selectively recognize Ag+ and Hg2+, to quantify the dual miRNAs concurrently. Under optimized conditions, the linear range was from 0.1 to 1000 fM and the limits of detection (LOD) for dual miRNAs reached 30 and 25 aM, respectively. The practicality was further evaluated with 45 clinical urine samples including prostate cancer (PC) and other patients, and the results were consistent with the clinical polymerase chain reaction (PCR) kit and ultrasonic and pathological findings. The receiver operating characteristic (ROC) curve analysis showed that the estimates of the area under the curve (AUC) were 0.739 for the serum prostate-specific antigen (PSA) and 0.941 for miRNA-375 and 0.946 for miRNA-148a. The sensitivity and specificity reached 75 and 100% for miRNA-375 and 71 and 94% for miRNA-148a, respectively, which was better than serum PSA. This strategy constructed a reliable system for dual miRNA detection in urine samples and proposed new insights into the rapid and noninvasive diagnosis of PC.

Urinary miR-16-5p can be used as a potential marker of endocapillary hypercellularity in IgA nephropathy

The most prevalent primary glomerulonephritis and leading cause of end-stage renal disease worldwide is IgA nephropathy (IgAN). More and more studies are describing urinary microRNA (miRNA) as a non-invasive marker for a variety of renal diseases. We screened candidate miRNAs based on data from three published IgAN urinary sediment miRNAs chips. In separate confirmation and validation cohorts, we included 174 IgAN patients, 100 patients with other nephropathies as disease controls (DC), and 97 normal controls (NC) for quantitative real-time PCR. A total of three candidate miRNAs, miR-16-5p, Let-7g-5p, miR-15a-5p were obtained. In both the confirmation and validation cohorts, these miRNAs levels were considerably higher in the IgAN than in NC, with miR-16-5p significantly higher than in DC. The area under the ROC curve for urinary miR-16-5p levels was 0.73. Correlation analysis suggested that miR-16-5p was positively correlated with endocapillary hypercellularity (r = 0.164 p = 0.031). When miR-16-5p was combined with eGFR, proteinuria and C4, the AUC value for predicting endocapillary hypercellularity was 0.726. By following the renal function of patients with IgAN, the levels of miR-16-5p were noticeably higher in the IgAN progressors than in the non- progressors (p = 0.036). Urinary sediment miR-16-5p can be used as noninvasive biomarkers for the assessment of endocapillary hypercellularity and diagnosis of IgA nephropathy. Furthermore, urinary miR-16-5p may be predictors of renal progression.

MP53-19 URINARY MICRORNAS ARE POTENTIAL BIOMARKERS OF SEVERITY OF URINARY TRACT DYSFUNCTION IN PATIENTS WITH POSTERIOR URETHRAL VALVES

You have accessJournal of UrologyCME1 Apr 2023MP53-19 URINARY MICRORNAS ARE POTENTIAL BIOMARKERS OF SEVERITY OF URINARY TRACT DYSFUNCTION IN PATIENTS WITH POSTERIOR URETHRAL VALVES Elizabeth Mann, Melissa Mogle, Aditi Paranjpe, Marion Schulte, and Pramod Reddy Elizabeth MannElizabeth Mann More articles by this author , Melissa MogleMelissa Mogle More articles by this author , Aditi ParanjpeAditi Paranjpe More articles by this author , Marion SchulteMarion Schulte More articles by this author , and Pramod ReddyPramod Reddy More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003301.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Current management strategy for patients presenting with posterior urethral valves (PUV) includes monitoring of renal function to determine when urinary tract (UT) intervention such as intermittent catheterization or urinary diversion is indicated. The challenge with this approach is that ongoing renal injury may no longer be reversible and exposes the child to progression of chronic kidney disease (CKD). We hypothesize that microRNAs (miRNA) derived from urinary small extracellular vesicles (sEV) reflect the physiological status of the UT and may serve as real-time indicators of lower urinary tract injury. These biomarkers could permit the development of a proactive strategy of serial monitoring of the lower UT in patients with PUV and permit timely intervention prior to the progression of renal injury. METHODS: We have undertaken an IRB approved prospective study. Informed consent was obtained at time of enrollment. Urine samples are collected for each patient at least once a year and urinalysis performed. We excluded samples with active infections. Patients (1-18 yrs) with PUV were stratified into clinical categories based on the severity of the involvement of their UT. Patients with isolated genital pathology and a normal UT served as negative controls. sEVs were isolated from the urine by ultracentrifugation and total RNA extracted. Next-generation small RNA sequencing and differential expression analysis was performed. RT-qPCR was used to verify the expression of candidate miRNAs. RESULTS: A total of 76 PUV Patients and 35 controls have been enrolled in the study, with 244 urine samples collected. Principle component analysis of the most variable miRNAs demonstrated a clear clustering of the patients in the moderate/severe category compared to the patients with mild disease and non-PUV controls. We have identified 61 miRNAs that were upregulated and 45 miRNAs that were downregulated in the moderate/severe patients (≥1.5-fold, p≤0.05). We selected 4 miRNAs to analyze further by RT-qPCR and confirmed the decreased expression of miRNA-30a-5p in moderate/severe cases (>5-fold, p≤0.01). CONCLUSIONS: This study demonstrates that urinary miRNAs can serve as biomarkers of the severity of UT dysfunction in patients with PUV. Ongoing studies seek to further validate these findings. The development of a noninvasive urinary assay for a set of predictive miRNA biomarkers will enhance our ability to care for patients with PUV and enable real-time assessment of the health of their lower urinary tract. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e719 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Elizabeth Mann More articles by this author Melissa Mogle More articles by this author Aditi Paranjpe More articles by this author Marion Schulte More articles by this author Pramod Reddy More articles by this author Expand All Advertisement PDF downloadLoading ...

Urinary exosomal microRNAs as predictive biomarkers for persistent psychotic-like experiences

Psychotic-like experiences (PLEs) occur occasionally in adolescence and mostly disappear with increasing age. Their presence, if persistent, is considered a robust risk factor for subsequent psychiatric disorders. To date, only a few biological markers have been investigated for persistent PLE prediction. This study identified urinary exosomal microRNAs that can serve as predictive biomarkers for persistent PLEs. This study was part of a population-based biomarker subsample study of the Tokyo Teen Cohort Study. A total of 345 participants aged 13 (baseline) and 14 (follow-up) years underwent PLE assessments by experienced psychiatrists using semi-structured interviews. We defined remitted and persistent PLEs based on longitudinal profiles. We obtained urine at baseline and the expression levels of urinary exosomal miRNAs were compared between 15 individuals with persistent PLEs and 15 age- and sex-matched individuals with remitted PLEs. We constructed a logistic regression model to examine whether miRNA expression levels could predict persistent PLEs. We identified six significant differentially expressed microRNAs, namely hsa-miR-486-5p, hsa-miR-199a-3p, hsa-miR-144-5p, hsa-miR-451a, hsa-miR-143-3p, and hsa-miR-142-3p. The predictive model showed an area under the curve of 0.860 (95% confidence interval: 0.713–0.993) for five-fold cross-validation. We found a subset of urinary exosomal microRNAs that were differentially expressed in persistent PLEs and presented the likelihood that a microRNA-based statistical model could predict them with high accuracy. Therefore, urine exosomal miRNAs may serve as novel biomarkers for the risk of psychiatric disorders.

Differential expression profile of urinary exosomal microRNAs in patients with mesangial proliferative glomerulonephritis.

To investigate the differential expression profile of urinary exosomal microRNA (miRNA) in patients with mesangial proliferative glomerulonephritis (MsPGN) and healthy controls and their potential role in the pathogenesis of MsPGN. Urine specimens were collected from five MsPGN patients and five healthy controls, and differentially expressed miRNAs were screened using high-throughput sequencing technology. The sequenced urinary exosomal miRNAs were further investigated by quantitative real-time polymerase chain reaction (qRT-PCR) in a validation cohort (16 MsPGN patients and 16 healthy controls). Correlation and receiver operating characteristic (ROC) curve analyses were used to determine the association between clinical features and miRNA expression in MsPGN. Finally, fluorescence in situ hybridization was performed to detect miRNA expression in the renal tissues of MsPGN patients. Five differentially expressed miRNAs (miR-125b-2-3p, miR-205-5p, let-7b-3p, miR-1262, and miR-548o-3p) were identified by qRT-PCR. The expression of these miRNAs correlated with ACR, 24hUpro, mAlb, UA, and combined yielded a ROC curve area of 0.916 in discriminating MsPGN patients from the controls. In addition, the expression of miR-205-5p, let-7b-3p, miR-1262, and miR-548o-3p was elevated in the MsPGN patient group, and miR-125b-2-3p was decreased in the MsPGN patient group. Differential expression of urinary exosomal miRNAs may pose a risk of MsPGN and help distinguish MsPGN patients from controls. Certain miRNA expressions may be associated with disease progression, contributing to the epigenetic understanding of the pathophysiology of MsPGN.